Clinical Report: Evaluating the Prognostic Effects of Statin Treatment in Patients with Hormone Receptor-Positive Breast Cancer
Overview
This meta-analysis evaluates the impact of statin use on recurrence and mortality in hormone receptor-positive (HR+) breast cancer patients. Findings indicate that statin therapy is associated with a significant reduction in both recurrence risk and mortality.
Background
Incorporate references to studies that support the claims about statins' anti-tumor effects.
Data Highlights
Outcome
Hazard Ratio (HR)
95% Confidence Interval (CI)
P-value
Recurrence Risk
0.77
0.61–0.98
0.03
Mortality
0.77
0.73–0.81
< 0.001
Key Findings
Statin use is associated with a 23% reduction in recurrence risk in HR+ breast cancer patients.
Statin therapy significantly decreases mortality in HR+ breast cancer, with a hazard ratio of 0.77.
The meta-analysis included data from 7 studies with a total of 267,913 HR+ breast cancer patients.
Sensitivity analyses confirmed the robustness of the findings regarding statin efficacy.
Statins may help mitigate endocrine therapy resistance in HR+ breast cancer due to their pleiotropic effects.
Clinical Implications
The findings suggest that statins could serve as a beneficial adjunctive therapy for patients with HR+ breast cancer, potentially improving survival outcomes. Clinicians should consider the implications of statin therapy in the management of HR+ breast cancer, especially in patients at risk of endocrine therapy resistance.
Conclusion
This comprehensive meta-analysis supports the protective role of statins against recurrence and mortality in HR+ breast cancer, warranting further investigation through large-scale, prospective trials.
